Cost‐effectiveness of screening and treatment for bacterial vaginosis in early pregnancy among women at low risk for preterm birth

Abstract

Screening and treatment for BV in early pregnancy may not reduce costs compared to no-screening in a population at low risk for preterm birth but would produce, at the same cost, more health benefits in terms of fewer peripartum infections and postpartum complications. However, it may be cost-saving if the rate of preterm deliveries is higher than 3%.